Clinical trialNCT04152837TerminatedPhase 3Interventional

Safety of Lixivaptan in Subjects Previously Treated With Tolvaptan for Autosomal Dominant Polycystic Kidney Disease

SponsorPalladio BiosciencesEnrollment7ADPKDPolycystic Kidney Disease, Adult

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a Phase 3, open-label, repeat-dose study designed to assess liver safety, non-liver safety, and efficacy of lixivaptan in participants who previously experienced liver chemistry test abnormalities while treated with tolvaptan and were permanently discontinued from the drug for that reason. Up to 50 eligible participants will be enrolled and treated with lixivaptan for 52 weeks following titration to an optimal dose.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Arlene Chapman, MD
University of Chicago, Chicago, IL USA
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

University of California Los Angeles
Los Angeles, California, United States
University of Chicago Medicine & Biological Sciences
Chicago, Illinois, United States
Mayo Clinic
Rochester, Minnesota, United States
Brookview Hills Research Associates, Llc
Winston-Salem, North Carolina, United States
Northeast Clinical Research Center, Llc
Bethlehem, Pennsylvania, United States
Nephrology Associates of Northern Virginia, Inc.
Fairfax, Virginia, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

LIXIVAPTAN

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 2 Sept 2020
Primary completion: 29 Jul 2022
Completion: 29 Jul 2022
Last update posted: 10 Apr 2023
Registered enrollment: 7
Registry id: NCT04152837

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.